m6A-centered Disease Response Information
General Information of the Disease (ID: M6ADIS0112)
Name |
Rheumatoid arthritis
|
||||
---|---|---|---|---|---|
ICD |
ICD-11: FA20
|
Full List of Target Gene(s) of This m6A-centered Disease Response
Interleukin-6 (IL-6)
In total 1 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [1] | |||
Response Summary | METTL3 knockdown suppressed Interleukin-6 (IL-6), matrix metalloproteinase (MMP)-3, and MMP-9 levels in human RA-FLSs and rat AIA-FLSs. | |||
Responsed Disease | Rheumatoid arthritis [ICD-11: FA20] | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Up regulation | |||
Cell Process | Inflammatory response | |||
In-vitro Model | FLS (Rat fibroblast synovial cell line) | |||
In-vivo Model | To establish the adjuvant-induced arthritis (AIA) model, the rats were given complete Freund's adjuvant (CFA; Chondrex, Inc.) on the left paw of 0.1 ml per 100 g of body weight. Additionally, the rats were injected with normal saline to create the negative control (NC) group. | |||
Matrix metalloproteinase-9 (MMP9)
In total 1 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [1] | |||
Response Summary | METTL3 knockdown suppressed interleukin (IL)-6, matrix metalloproteinase (MMP)-3, and Matrix metalloproteinase-9 (MMP9) levels in human RA-FLSs and rat AIA-FLSs. | |||
Responsed Disease | Rheumatoid arthritis [ICD-11: FA20] | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Up regulation | |||
Cell Process | Inflammatory response | |||
In-vitro Model | FLS (Rat fibroblast synovial cell line) | |||
In-vivo Model | To establish the adjuvant-induced arthritis (AIA) model, the rats were given complete Freund's adjuvant (CFA; Chondrex, Inc.) on the left paw of 0.1 ml per 100 g of body weight. Additionally, the rats were injected with normal saline to create the negative control (NC) group. | |||
Protein-glutamine gamma-glutamyltransferase 2 (TGM2)
In total 1 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [2] | |||
Response Summary | In rheumatoid arthritis fibroblast-like synoviocytes, m6A methylation-mediated gene Protein-glutamine gamma-glutamyltransferase 2 (TGM2) served as a promoter of RA-FLS proliferation by inducing DNA replication and cell cycle transition and inhibiting apoptosis through activating NF-Kappa-B signaling. TGM2 can be an attractive target and Sar was a novel anti-RA drug. | |||
Responsed Disease | Rheumatoid arthritis [ICD-11: FA20] | |||
Responsed Drug | Sarsasapogenin | Investigative | ||
Pathway Response | DNA replication | hsa03030 | ||
Cell Process | DNA replication | |||
Cell apoptosis | ||||
In-vitro Model | MH7A | Normal | Homo sapiens | CVCL_0427 |
Receptor-interacting serine/threonine-protein kinase 2 (RIPK2)
In total 1 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [3] | |||
Response Summary | This study established the transcriptional map of m6A in MH7A cells and revealed the potential relationship between RNA methylation modification and rheumatoid arthritis related genes. The results suggested that m6A modification was associated with the occurrence and course of RA to some extent. The validations of WTAP, Receptor-interacting serine/threonine-protein kinase 2 (RIPK2), JAK3 and TNFRSF10A were in accordance with the m6A and RNA sequencing results. | |||
Responsed Disease | Rheumatoid arthritis [ICD-11: FA20] | |||
Target Regulator | Wilms tumor 1-associating protein (WTAP) | WRITER | ||
Pathway Response | JAK-STAT signaling pathway | hsa04630 | ||
Cytokine-cytokine receptor interaction | hsa04060 | |||
Cell Process | Cell proliferation | |||
Cell apoptosis | ||||
In-vitro Model | MH7A | Normal | Homo sapiens | CVCL_0427 |
In-vivo Model | The rats were adaptively fed for 1 week and then subcutaneous injection of complete Freund's adjuvant into the left hindfoot toe to establish an adjuvant arthritis (AA) rat model. After induction of the immune response for 20 days, all rats were anesthetized by the intraperitoneal injection of 1% sodium pentobarbital (60 mg/kg) and sacrificed by exsanguination of the abdominal aorta. | |||
Stromelysin-1 (MMP-3)
In total 1 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [1] | |||
Response Summary | METTL3 knockdown suppressed interleukin (IL)-6, matrix metalloproteinase Stromelysin-1 (MMP-3), and MMP-9 levels in human RA-FLSs and rat AIA-FLSs. | |||
Responsed Disease | Rheumatoid arthritis [ICD-11: FA20] | |||
Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
Target Regulation | Up regulation | |||
Cell Process | Inflammatory response | |||
In-vitro Model | FLS (Rat fibroblast synovial cell line) | |||
In-vivo Model | To establish the adjuvant-induced arthritis (AIA) model, the rats were given complete Freund's adjuvant (CFA; Chondrex, Inc.) on the left paw of 0.1 ml per 100 g of body weight. Additionally, the rats were injected with normal saline to create the negative control (NC) group. | |||
Tumor necrosis factor receptor superfamily member 10A (TNFRSF10A)
In total 1 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [3] | |||
Response Summary | This study established the transcriptional map of m6A in MH7A cells and revealed the potential relationship between RNA methylation modification and rheumatoid arthritis related genes. The results suggested that m6A modification was associated with the occurrence and course of RA to some extent. The validations of WTAP, RIPK2, JAK3 and Tumor necrosis factor receptor superfamily member 10A (TNFRSF10A) were in accordance with the m6A and RNA sequencing results. | |||
Responsed Disease | Rheumatoid arthritis [ICD-11: FA20] | |||
Target Regulator | Wilms tumor 1-associating protein (WTAP) | WRITER | ||
Pathway Response | JAK-STAT signaling pathway | hsa04630 | ||
Cytokine-cytokine receptor interaction | hsa04060 | |||
Cell Process | Cell proliferation | |||
Cell apoptosis | ||||
In-vitro Model | MH7A | Normal | Homo sapiens | CVCL_0427 |
In-vivo Model | The rats were adaptively fed for 1 week and then subcutaneous injection of complete Freund's adjuvant into the left hindfoot toe to establish an adjuvant arthritis (AA) rat model. After induction of the immune response for 20 days, all rats were anesthetized by the intraperitoneal injection of 1% sodium pentobarbital (60 mg/kg) and sacrificed by exsanguination of the abdominal aorta. | |||
Tyrosine-protein kinase JAK3 (JAK3)
In total 1 item(s) under this target gene | ||||
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [3] | |||
Response Summary | This study established the transcriptional map of m6A in MH7A cells and revealed the potential relationship between RNA methylation modification and rheumatoid arthritis related genes. The results suggested that m6A modification was associated with the occurrence and course of RA to some extent. The validations of WTAP, RIPK2, Tyrosine-protein kinase JAK3 (JAK3) and TNFRSF10A were in accordance with the m6A and RNA sequencing results. | |||
Responsed Disease | Rheumatoid arthritis [ICD-11: FA20] | |||
Target Regulator | Wilms tumor 1-associating protein (WTAP) | WRITER | ||
Pathway Response | JAK-STAT signaling pathway | hsa04630 | ||
Cytokine-cytokine receptor interaction | hsa04060 | |||
Cell Process | Cell proliferation | |||
Cell apoptosis | ||||
In-vitro Model | MH7A | Normal | Homo sapiens | CVCL_0427 |
In-vivo Model | The rats were adaptively fed for 1 week and then subcutaneous injection of complete Freund's adjuvant into the left hindfoot toe to establish an adjuvant arthritis (AA) rat model. After induction of the immune response for 20 days, all rats were anesthetized by the intraperitoneal injection of 1% sodium pentobarbital (60 mg/kg) and sacrificed by exsanguination of the abdominal aorta. | |||
References